Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives

Valentina Guarneri, Antonio Frassoldati, Simona Giovannelli, Francesca Borghi, PierFranco Conte

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.

Original languageEnglish
Pages (from-to)175-185
Number of pages11
JournalCancer Letters
Volume248
Issue number2
DOIs
Publication statusPublished - Apr 18 2007

Fingerprint

Clinical Trials
Breast Neoplasms
Therapeutics
Standard of Care
Breast
Drug Therapy

Keywords

  • Breast cancer
  • Primary chemotherapy
  • Primary endocrine therapy
  • Primary targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Primary systemic therapy for operable breast cancer : A review of clinical trials and perspectives. / Guarneri, Valentina; Frassoldati, Antonio; Giovannelli, Simona; Borghi, Francesca; Conte, PierFranco.

In: Cancer Letters, Vol. 248, No. 2, 18.04.2007, p. 175-185.

Research output: Contribution to journalArticle

Guarneri, Valentina ; Frassoldati, Antonio ; Giovannelli, Simona ; Borghi, Francesca ; Conte, PierFranco. / Primary systemic therapy for operable breast cancer : A review of clinical trials and perspectives. In: Cancer Letters. 2007 ; Vol. 248, No. 2. pp. 175-185.
@article{ef59f2919a454e2aa487c508d5092f82,
title = "Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives",
abstract = "Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.",
keywords = "Breast cancer, Primary chemotherapy, Primary endocrine therapy, Primary targeted therapy",
author = "Valentina Guarneri and Antonio Frassoldati and Simona Giovannelli and Francesca Borghi and PierFranco Conte",
year = "2007",
month = "4",
day = "18",
doi = "10.1016/j.canlet.2006.07.001",
language = "English",
volume = "248",
pages = "175--185",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Primary systemic therapy for operable breast cancer

T2 - A review of clinical trials and perspectives

AU - Guarneri, Valentina

AU - Frassoldati, Antonio

AU - Giovannelli, Simona

AU - Borghi, Francesca

AU - Conte, PierFranco

PY - 2007/4/18

Y1 - 2007/4/18

N2 - Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.

AB - Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.

KW - Breast cancer

KW - Primary chemotherapy

KW - Primary endocrine therapy

KW - Primary targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=33847255913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847255913&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2006.07.001

DO - 10.1016/j.canlet.2006.07.001

M3 - Article

C2 - 16919869

AN - SCOPUS:33847255913

VL - 248

SP - 175

EP - 185

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -